Cover Image
市場調查報告書

PharmaPoint:帕金森氏症 - EU5個國家的醫藥品的預測與市場分析

PharmaPoint: Parkinson's Disease - 5EU Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 301425
出版日期 內容資訊 英文 249 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:帕金森氏症 - EU5個國家的醫藥品的預測與市場分析 PharmaPoint: Parkinson's Disease - 5EU Drug Forecast and Market Analysis to 2022
出版日期: 2014年03月31日 內容資訊: 英文 249 Pages
簡介

帕金森氏症的症狀是以動作緩慢、肌肉僵硬、震顫和姿勢不穩為特徵的一個漸進式疾病。是發病率第二高的神經退化性疾病,無論何種年齡層都有受到影響的可能性,得病率隨著年齡增長而上升,高齡者更是常見。雖然多巴胺療法對動作遲緩相當有效,但仍留有許多未滿足需求。

本報告提供EU5個國家帕金森氏症治療藥市場相關的調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),彙整SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
    • 預測
    • QOL
  • 症狀

第4章 疾病的管理

  • 概要
  • 治療概要
  • 帕金森氏症的評估規模
  • 帕金森氏症的診斷和治療:各國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介 - 左旋多巴混合製劑
  • 產品簡介 - COMT抑制劑
  • 多巴胺受體激動劑
  • 產品簡介 - MAO-B抑制劑
  • 產品簡介 - AdenosineA2A受體拮抗劑
  • 產品簡介 - 其他治療方法

第6章 機會及未滿足需求

  • 概要
  • 運動併發症的治療
  • 非運動併發症的治療
  • 神經保護/疾病修飾劑
  • 改善藥物配方
  • 可靠性高的生物標記
  • 改善臨床試驗的設計

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
    • Safinamide
    • Tozadenant
    • CVT-301
    • Rytary/IPX066
    • Opicapone
    • Mavoglurant/AFQ056
    • CD/LD-GR
    • 其他後期開發中產品

第8章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Merck
    • Roche
    • AbbVie
    • UCB
    • GlaxoSmithKline
    • Novartis
    • Orion
    • Newron
    • Civitas
    • Impax
    • Lundbeck

第9章 市場預測

  • 推動因素與阻礙 - 全球問題點
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第10章 附錄

圖表

目錄
Product Code: GDHC236CFR

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Although France has a lower-than-average rate of generic substitution compared with other parts of Europe, increasing pressures from its aging population and increased disease burden are forcing governments to institute cost-saving measures. The market leader therapies in Germany are all no longer patent protected and include the class of oral dopamine agonists. While the overall pharmaceutical market in Italy is shrinking, the medical device market in Italy is growing. This market growth will be driven by six new product launches, and by an aging population, resulting in an increased prevalence of Parkinson's disease in Spain. Population growth and the aging population will continue to build steady growth in the UK Parkinson's disease market and six additional product launches, including the introduction of A2A antagonists in 2019, will bring in an extra $24.7m in sales in 2022.

Scope

  • Overview of Parkinson's Disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Parkinson's Disease market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Parkinson's Disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in 5EU

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Overview
    • 4.1.1. Diagnosis - The UK Brain Bank Criteria
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
  • 4.2. Treatment Synopsis
    • 4.2.1. Dopaminergic Therapy Classes
    • 4.2.2. Treatment of Parkinson's disease by Stage
    • 4.2.3. Other Treatment Options
  • 4.3. Parkinson's Disease Assessment Scales
    • 4.3.1. Unified Parkinson's Disease Rating Scale (UPDRS)
    • 4.3.2. Hoehn and Yahr Clinical Staging
    • 4.3.3. Other Clinical Assessments
  • 4.4. Diagnosis and Treatment of Parkinson's Disease by Country
    • 4.4.1. France
    • 4.4.2. Germany
    • 4.4.3. Italy
    • 4.4.4. Spain
    • 4.4.5. UK

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Levodopa Combination Therapy
    • 5.3.1. Madopar (levodopa/benserazide)
    • 5.3.2. Sinemet (carbidopa/levodopa)
    • 5.3.3. Duodopa (carbidopa/levodopa intestinal gel)
  • 5.4. Product Profiles - COMT Inhibitors
    • 5.4.1. Stalevo/Comtan (entacapone)
  • 5.5. Dopamine Agonists
    • 5.5.1. Neupro (rotigotine transdermal patch)
    • 5.5.2. Requip/Requip XL (ropinirole)
    • 5.5.3. Apokyn (apomorphine)
  • 5.6. Product Profiles - MAO-B Inhibitors
    • 5.6.1. Azilect (rasagiline)
  • 5.7. Product Profiles - Adenosine 2A Inhibitor
    • 5.7.1. Nouriast (istradefylline)
  • 5.8. Product Profiles - Other Therapies

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Treatment of Motor Complications - Dyskinesias and OFF Episodes
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Treatment of Non-Motor Symptoms and Dementia
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Neuroprotective/Disease-Modifying Agents
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Improved Drug Formulations
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Identification of Reliable Biomarkers
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Improved Clinical Trial Design
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Safinamide
    • 7.2.2. Tozadenant
    • 7.2.3. CVT-301
    • 7.2.4. Rytary/IPX066
    • 7.2.5. Opicapone
    • 7.2.6. Mavoglurant/AFQ056
    • 7.2.7. CD/LD-GR
    • 7.2.8. Other Late-Stage Pipeline Products

8. Current and Future Players

  • 8.1. Overview
  • 8.2. Trends in Corporate Strategy
  • 8.3. Company Profiles
    • 8.3.1. Merck
    • 8.3.2. Roche
    • 8.3.3. AbbVie
    • 8.3.4. UCB
    • 8.3.5. GlaxoSmithKline
    • 8.3.6. Novartis
    • 8.3.7. Orion
    • 8.3.8. Newron
    • 8.3.9. Civitas
    • 8.3.10. Impax
    • 8.3.11. Lundbeck

9. Market Outlook

  • 9.1. Drivers and Barriers - Global Issues
    • 9.1.1. Driver: Aging Population
    • 9.1.2. Driver: Launch of Products that Will Add Patient Share
    • 9.1.3. Driver: High Compliance Rates
    • 9.1.4. Driver: History of Success in PD Market
    • 9.1.5. Driver: Innovation and Technological Advances
    • 9.1.6. Driver: High Degree of Polypharmacy
    • 9.1.7. Barrier: Lack of Understanding of Pathophysiology
    • 9.1.8. Barrier: Lack of Efficacy of New Compounds
    • 9.1.9. Barrier: Strategic Decisions to Leave CNS Space for Several Large Pharma Companies
  • 9.2. France
    • 9.2.1. Forecast
    • 9.2.2. Key Events
    • 9.2.3. Drivers and Barriers
  • 9.3. Germany
    • 9.3.1. Forecast
    • 9.3.2. Key Events
    • 9.3.3. Drivers and Barriers
  • 9.4. Italy
    • 9.4.1. Forecast
    • 9.4.2. Key Events
    • 9.4.3. Drivers and Barriers
  • 9.5. Spain
    • 9.5.1. Forecast
    • 9.5.2. Key Events
    • 9.5.3. Drivers and Barriers
  • 9.6. UK
    • 9.6.1. Forecast
    • 9.6.2. Key Events
    • 9.6.3. Drivers and Barriers

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed Parkinson's Disease Patients
    • 10.4.2. Percent Drug-Treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Compliance Assumptions
    • 10.4.7. Individual Drug Assumptions
    • 10.4.8. Generic Erosion
    • 10.4.9. Pricing of Pipeline Agents
  • 10.5. Physicians and Specialists Included in this Study
  • 10.6. About the Authors
    • 10.6.1. Author
    • 10.6.2. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Parkinson's Disease
  • Table 2: UK Brain Bank Diagnostic Criteria
  • Table 3: Diagnosis and Treatment Guidelines for Parkinson's Disease
  • Table 4: Most Prescribed Drugs for Parkinson's Disease by Class in the Global Markets, 2014
  • Table 5: Dopaminergic Therapy in Parkinson's Disease
  • Table 6: UPDRS Clinical Assessment of Disease Severity
  • Table 7: Parkinson's Disease Assessment Scales Used in Clinical Trials
  • Table 8: Parkinson's Disease, Country Profile - France
  • Table 9: Parkinson's Disease, Country Profile - Germany
  • Table 10: Parkinson's Disease, Country Profile - Italy
  • Table 11: Parkinson's Disease, Country Profile - Spain
  • Table 12: Parkinson's Disease, Country Profile - UK
  • Table 13: Treatment of Motor Symptoms in Parkinson's Disease
  • Table 14: Leading Treatments for Parkinson's Disease, 2014
  • Table 15: Product Profile - Madopar
  • Table 16: Madopar SWOT Analysis, 2014
  • Table 17: Product Profile - Sinemet
  • Table 18: Sinemet SWOT Analysis, 2014
  • Table 19: Product Profile - Duodopa
  • Table 20: Duodopa SWOT Analysis, 2014
  • Table 21: Product Profile - Stalevo
  • Table 22: Product Profile - Comtan
  • Table 23: Stalevo/Comtan SWOT Analysis, 2014
  • Table 24: Product Profile - Neupro
  • Table 25: Neupro SWOT Analysis, 2014
  • Table 26: Product Profile - Requip/Requip XL
  • Table 27: Requip/Requip XL SWOT Analysis, 2014
  • Table 28: Product Profile - Apokyn
  • Table 29: Apokyn SWOT Analysis, 2014
  • Table 30: Product Profile - Azilect
  • Table 31: Azilect SWOT Analysis, 2014
  • Table 32: Product Profile - Nouriast
  • Table 33: Nouriast SWOT Analysis, 2014
  • Table 34: Summary of Alternative Parkinson's Disease Therapies
  • Table 35: Unmet Need and Opportunity in Parkinson's Disease
  • Table 36: Dyskinesia Pipeline, 2014
  • Table 37: Dementia Pipeline, 2014
  • Table 38: Parkinson's Disease-Modifying Therapeutics Pipeline, 2014
  • Table 39: Product Profile - Safinamide
  • Table 40: Summary of Relevant Clinical Trials for Safinamide
  • Table 41: Safinamide SWOT Analysis, 2014
  • Table 42: Product Profile - Tozadenant
  • Table 43: Tozadenant SWOT Analysis, 2014
  • Table 44: Product Profile - CVT-301
  • Table 45: CVT-301 SWOT Analysis, 2014
  • Table 46: Product Profile - Rytary
  • Table 47: Rytary SWOT Analysis, 2014
  • Table 48: Product Profile - Opicapone
  • Table 49: Opicapone SWOT Analysis, 2014
  • Table 50: Product Profile - Mavoglurant
  • Table 51: Mavoglurant SWOT Analysis, 2014
  • Table 52: Product Profile - CD/LD-GR
  • Table 53: Summary of Relevant Clinical Trials for CD/LD-GR
  • Table 54: CD/LD-GR SWOT Analysis, 2014
  • Table 55: Late-Stage Pipeline, 2013
  • Table 56: Key Companies in the Parkinson's Market, 2014
  • Table 57: Merck's Parkinson's Disease Portfolio Assessment, 2014
  • Table 58: Merck's PD SWOT Analysis, 2014
  • Table 59: Roche's Parkinson's Disease Portfolio Assessment, 2014
  • Table 60: Roche's PD SWOT Analysis, 2014
  • Table 61: AbbVie's Parkinson's Disease Portfolio Assessment, 2014
  • Table 62: AbbVie's PD SWOT Analysis, 2014
  • Table 63: UCB's Parkinson's Disease Portfolio Assessment, 2014
  • Table 64: UCB's PD SWOT Analysis, 2014
  • Table 65: GSK's Parkinson's Disease Portfolio Assessment, 2014
  • Table 66: GSK's PD SWOT Analysis, 2014
  • Table 67: Novartis' Parkinson's Disease Portfolio Assessment, 2014
  • Table 68: Novartis' PD SWOT Analysis, 2014
  • Table 69: Orion's Parkinson's Disease Portfolio Assessment, 2014
  • Table 70: Orion's PD SWOT Analysis, 2014
  • Table 71: Newron's Parkinson's Disease Portfolio Assessment, 2014
  • Table 72: Newron's PD SWOT Analysis, 2014
  • Table 73: Civitas' Parkinson's Disease Portfolio Assessment, 2014
  • Table 74: Civitas' PD SWOT Analysis, 2014
  • Table 75: Impax's Parkinson's Disease Portfolio Assessment, 2014
  • Table 76: Impax's PD SWOT Analysis, 2014
  • Table 77: Lundbeck's Disease/Therapy Portfolio Assessment, 2014
  • Table 78: Lundbeck's SWOT Analysis, 2014
  • Table 79: Parkinson's Disease Market - Drivers and Barriers, 2012-2022
  • Table 80: Sales Forecasts ($m) for Parkinson's Disease in France, 2012-2022
  • Table 81: Key Events Impacting Sales for Parkinson's Disease in France, 2012-2022
  • Table 82: Parkinson's Disease Market in France - Drivers and Barriers, 2012-2022
  • Table 83: Sales Forecasts ($m) for Parkinson's Disease in Germany, 2012-2022
  • Table 84: Key Events Impacting Sales for Parkinson's Disease in Germany, 2012-2022
  • Table 85: Parkinson's Disease Market in Germany - Drivers and Barriers, 2012-2022
  • Table 86: Sales Forecasts ($) for Parkinson's Disease in Italy, 2012-2022
  • Table 87: Key Events Impacting Sales for Parkinson's Disease in Italy, 2012-2022
  • Table 88: Parkinson's Disease Market in Italy - Drivers and Barriers, 2012-2022
  • Table 89: Sales Forecasts ($m) for Parkinson's Disease in Spain, 2012-2022
  • Table 90: Key Events Impacting Sales for Parkinson's Disease in Spain, 2012-2022
  • Table 91: Parkinson's Disease Market in Spain - Drivers and Barriers, 2012-2022
  • Table 92: Sales Forecasts ($m) for Parkinson's Disease in the UK, 2012-2022
  • Table 93: Key Events Impacting Sales for Parkinson's Disease in the UK, 2012-2022
  • Table 94: Parkinson's Disease Market in the UK - Drivers and Barriers, 2012-2022
  • Table 95: Key Launch Dates
  • Table 96: Key Patent Expiries

List of Figures

  • Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes
  • Figure 2: Overview - Treatment of Motor Symptoms of Parkinson's Disease
  • Figure 3: Pharmacokinetics of Levodopa
  • Figure 4: Parkinson's Disease - Phase II-III Pipeline, Segmented by Indication, 2014
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Parkinson's Disease, 2012-2022
  • Figure 6: Company Portfolio Gap Analysis in Parkinson's Motor Symptoms, 2012-2022
  • Figure 7: Sales for Parkinson's Disease in France by Drug Class, 2012-2022
  • Figure 8: Sales for Parkinson's Disease in Germany by Drug Class, 2012-2022
  • Figure 9: Sales for Parkinson's Disease in Italy by Drug Class, 2012-2022
  • Figure 10: Sales for Parkinson's Disease in Spain by Drug Class, 2012-2022
  • Figure 11: Sales for Parkinson's Disease in the UK by Drug Class, 2012-2022
Back to Top